FSD Pharma Inc. (HUGE)
Stock Price:
$1.42 USD
-0.13 (-8.39%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
21.08M |
| Revenue (ttm) |
196,259 |
| Net Income (ttm) |
-39.70M |
| Shares Out |
14.84M |
| EPS (ttm) |
-5.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$1.42 |
| Previous Close |
$1.55 |
| Change ($) |
-0.13 |
| Change (%) |
-8.39% |
| Day's Open |
1.58 |
| Day's Range |
1.38 - 1.64 |
| Day's Volume |
252,042 |
| 52-Week Range |
1.38 - 14.00 |
More Stats
| Market Cap |
21.08M |
| Enterprise Value |
16.63M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.84M |
| Float |
11.66M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-5.63 |
| FCF / Share |
-2.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
75,456 |
| Short Ratio |
0.46 |
| Short % of Float |
0.65% |
| Beta |
0.54 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
107.40 |
| PB Ratio |
0.87 |
| Revenue |
196,259 |
| Operating Income |
-27.99M |
| Net Income |
-39.70M |
| Free Cash Flow |
-14.62M |
| Net Cash |
4.44M |
| Net Cash / Share |
0.30 |
| Gross Margin |
-936.22% |
| Operating Margin |
-14,262.99% |
| Profit Margin |
-20,230.80% |
| FCF Margin |
-7,449.07% |
| ROA |
-41.75% |
| ROE |
-93.65% |
| ROIC |
-206.90% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
11.0
Current: $1.42
High
11.0
Target: 11.00
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 0.26 | - | 0.03 |
| Gross Profit | -2.41 | - | 0.03 |
| Operating Income | -36.67 | -32.86 | -3.52 |
| Net Income | -52.01 | -22.71 | -3.52 |
| Shares Outstanding | 7.06 | 5.91 | 2.19 |
| Earnings Per Share | -7.37 | -3.85 | - |
| Operating Cash Flow | -18.23 | -18.49 | -0.15 |
| Capital Expenditures | -0.92 | -4.03 | -7.65 |
| Free Cash Flow | -19.15 | -22.52 | -7.80 |
| Cash & Equivalents | 7.93 | 21.13 | 4.74 |
| Total Debt | 2.11 | - | - |
| Net Cash / Debt | 5.82 | 21.13 | 4.74 |
| Assets | 57.45 | 52.78 | 13.68 |
| Liabilities | 9.23 | 1.74 | 1.27 |
| Book Value | 48.22 | 51.03 | 12.41 |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
FSD Pharma Inc. |
| Country |
Canada |
| Employees |
17 |
| CEO |
Raza Bokhari |
Stock Information
| Ticker Symbol |
HUGE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: HUGE |
Description
FSD Pharma, through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.